Navigation Links
NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir

A pre-grant opposition has been filed against the anti-HIV drug, Combivir, manufactured by GlaxoSmithKline, a leading pharmaceutical company //. The Manipur Network of Positive People (MNP+) and the Indian Network of People Living with HIV/AIDS have lodged the complaint at the Kolkata patent office.

The drug formulation is a combination of two essential anti-HIV drugs Lamivudine and Zidovudine and is not a new formulation, said a release. The grant of a patent is believed to make the anti-retroviral treatment expensive for patients afflicted with the deadly disease.

'We are objecting to the patenting of Combivir because it is not a new invention but simply the combination of two existing drugs,' said K K Abraham, president, INP+.

A similar opposition was raised regarding patenting anti-cancer drug, Gleevac, manufactured by Novartis. The patent was turned down subsequently as it was found to nothing more than a new form of an old drug.

Combivir is one of the anti-retroviral drugs used by numerous AIDS/HIV organizations, worldwide. A fixed dose combination of the drug is used in several projects targeted at provision of cheap and effective AIDS/HIV treatment to those who cannot afford the same.

In India, more than 5.1 million people are afflicted with AIDS/HIV and a majority of these are solely dependent on the generic drugs provided by the national HIV/AIDS treatment program. The issue of a patent can lead to domination with respect to drug manufacture, thereby restricting the production of effective and affordable drug alternatives.


'"/>




Page: 1

Related medicine news :

1. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
2. Venus Remedies Files 5th International Patent Application
3. AIIMS Official Files Complaint Against Venugopal
4. Glaxo Files Cancer Drug For Approval With FDA
5. Queensland Opposition not happy over hiring consultancy
6. Opposition: Government turned a deaf ear to warnings about dwindling health care services
7. Kleins Third Way Has Tough Opposition
8. Opposition to Compulsory Fortification of Bread with Folic Acid
9. Opposition against Amendments in the Intellectual Property Law
10. Madhya Pradesh Begins Surya Namaskar Amid Muslim Opposition
11. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the ... use of health IT to create efficiencies in healthcare information exchange and a trusted ... 2017 Summer Forum which featured keynote addresses by Donald W. Rucker, MD, head ...
(Date:8/23/2017)... Ogden, Utah (PRWEB) , ... August 23, 2017 , ... ... 2013. , Give Back Day is a time Nightingale College dedicates to serving ... with organizations that thrive on donations and volunteers or those that need a little ...
(Date:8/23/2017)... ... August 23, 2017 , ... Boling Vision ... home to Indiana, and is now seeing patients at Boling Vision Center’s Elkhart ... in the diagnosis and treatment of eye disease, medical retina, high-technology cataract surgery, ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC Advantage ... - for Risk Management Solution Innovations and Security Solution for Government Innovations. Both ... in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , The ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing ... Relief with the 2017 Women’s Choice Award. The identification by women of an ... of 4 migraine sufferers are women. In a survey taken by the Women’s Choice ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: